Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255656 · ClinicalTrials.gov registry record · Phase 4
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
A Phase 4 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,062
- Enrollment target
NCT02255656 is a Phase 4 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 1,062 participants.
The verdict
NCT02255656, a Phase 4 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,062 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: * To evaluate long term efficacy of alemtuzumab. * To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment. * To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab. * To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Interventions
- DRUG alemtuzumab GZ402673
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,062 participants |
| Start Date | 2015-01-07 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255656
The ClinicalTrials.gov registry entry for NCT02255656 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,062 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alemtuzumab GZ402673 is the first listed.
NCT02255656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255656 about?
NCT02255656 is a clinical study titled "Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409". Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: * To evaluate long term efficacy of alemtuzumab. * To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment. * To evaluate participant-r...
What is the current status of trial NCT02255656?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,062 participants. The study started on 2015-01-07. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT02255656?
The interventions under investigation include: alemtuzumab GZ402673 (DRUG).
Who is sponsoring clinical trial NCT02255656?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.